PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Cenobamate - Epilepsy
PAD Profile : Cenobamate - Epilepsy
Keywords :
Focal onset seizures
Brand Names Include :
Ontozry
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Eslicarbazepine acetate
- Carbamazepine
- Clobazam
- Lacosamide
- Clonazepam
- Perampanel
- Ethosuximide
- Felbamate
- Rufinamide
- Gabapentin
- Stiripentol
- Lamotrigine
- Zonisamide
- Levetiracetam
- Oxcarbazepine
- Phenobarbital
- Piracetam
- Phenytoin
- Pregabalin
- Topiramate
- Sodium valproate
- Brivaracetam
- Sodium valproate
- Cannabidiol
- Vigabatrin
- Primidone
- Tiagabine
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Evidence Review
Committee Recommendations
Date
Committee Name
Narrative
02 March 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends the use of cenobamate in the treatments of focal onset seizures in epilepsy, in line with NICE guidance (TA753).
A RED traffic light status will be applied to cenobamate for this indication.
Associated BNF Codes
04. Central Nervous System
04.08.01. Control of epilepsy